Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has provided an announcement.
Jiangsu Hengrui Pharmaceuticals has disclosed the current composition of its board of directors, listing six executive directors, one non-executive director and four independent non-executive directors. The mix of roles indicates a broad governance structure intended to balance management oversight with independent supervision.
The company has also detailed the membership of four key board committees: audit, remuneration and evaluation, nomination, and strategy. By clarifying committee leadership and membership, Hengrui signals a structured approach to corporate governance and risk control, which is material for investors tracking oversight quality and strategic decision-making in the group.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$92.00 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a China-based pharmaceutical company listed in Hong Kong under stock code 1276. It operates in the pharmaceutical industry, focusing on the development and commercialization of medicines, and is governed by a board comprising executive, non-executive and independent non-executive directors to oversee its strategic and governance functions.
Average Trading Volume: 3,291,704
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$438.2B
See more insights into 1276 stock on TipRanks’ Stock Analysis page.